Advanced Glycation End Products Market, By Type (Non-fluorescent AGEs and Fluorescent AGEs), By Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025

Code : CMI4350

Pages :105

Formats :

Excel and PDF

Industry : Pharmaceutical

Advanced Glycation End Products Market Size and Trends

Global advanced glycation end products market is estimated to be valued at US$ 1.87 Bn in 2025 and is expected to reach US$ 3.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.0% from 2025 to 2032.

Advanced Glycation End Products Market Key Factors

To learn more about this report, Request sample copy

Rising burden of diabetes and increasing adoption of unhealthy lifestyle habits can drive the market growth. Increasing investment by major market players for the development of novel drugs for the treatment of diabetes-related can also drive the market growth. Furthermore, growing obesity rates worldwide along with increasing geriatric population prone to diabetes and associated co-morbidities can drive the market growth over the forecast period.

Increasing prevalence of diabetes and obesity

Rising prevalence of diabetes and obesity can drive the market growth. Diabetes, in particular type 2 diabetes, is a major risk factor for the development of advanced glycation end products in the body. When blood sugar levels remain elevated for prolonged periods in diabetes, it leads to non-enzymatic glycation of proteins and lipids through a chain of complex chemical reactions. This process of glycation and the subsequent rearrangement of amino acids forms AGEs. Similarly, obesity is a chronic metabolic condition characterized by increased adiposity and insulin resistance, often preceding the onset of type 2 diabetes. The accumulation of excess body fat promotes oxidative stress and inflammation in tissues, two pathogenic processes strongly linked to AGE formation. As per estimates by health organizations, the total number of adults with diabetes had nearly quadrupled worldwide between 1980 to 2014. Rising prevalence of diabetes and obesity contributes to a greater disease burden from AGEs. This boosts demand for anti-AGE therapeutics. For instance, on June 23, 2025, according to the studies presented at the ADA's 84th Scientific Sessions in Orlando, advancements in GLP-1 receptor agonists can treat obesity. These developments come amid increasing concerns as obesity affects 125 million Americans, including 41.9% of adults and 19.7% of children. With 90% of diabetes patients grappling with overweight or obesity, the research aims to provide new solutions globally, according to Dr. Robert Gabbay,chief scientific and medical officer.